Abstract: The method of the invention comprises the production of highly digestible hydrolysed keratinaceous material comprising the steps of (i) partly hydrolysing keratinaceous material with heat and pressure and (ii) optionally drying the resultant partly hydrolysed material comprising at least partly insoluble material and (iii) subjecting the optionally dried partly hydrolysed keratinaceous material to a chemical hydrolysis step with acid or base to obtain a highly digestible hydrolysed material, and (iv) purifying the highly digestible material. The invention further provides highly digestible keratinaceous material with an amino acid composition reflecting the amino acid composition of the raw material, wherein the amount of de-carboxylated amino acids is less than 500 ppm. Preferably all of the highly digestible material has a molecular weight lower than 10000 dalton, and preferably more than 95 wt % of the highly digestible keratinaceous material has a molecular weight of less than 5000 dalton.

Abstract: Therapeutic regimens and uses of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates comprising a polyethylene glycol (PEG) moiety attached to a mutant FGF-21 peptide via a glycosyl moiety thereof in the treatment of nonalcoholic steatohepatitis are provided.

Abstract: The template-fixed ?-hairpin peptidomimetics Cyclo(-Tyr-His-X-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with X being Ala or Tyr, have CXCR4 antagonizing properties and can be used for where cancer is mediated or resulting from CXCR4 receptor activity.

Abstract: The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Abstract: There is provided a novel adrenomedullin derivative capable of sustainably acting for a longer period than natural adrenomedullin. The invention relates to a compound represented by formula (I): A-Ln-B (I), wherein A is a modifying group selected from the group consisting of a palmitoyl group and a polyethylene glycol group, L is a divalent linking group, n is an integer of 0 or 1, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is bound to the modifying group A or the linking group L via the N-terminal amino group of the peptide moiety B, or a salt thereof, or a hydrate thereof.

Abstract: A method for treating eye inflammation by using an anti-inflammatory composition is provided. The bioactive compound in the anti-inflammatory composition is a peptide having an amino acid sequence as set forth in SEQ ID NO.: 1. The amino acid sequence is a peptide fragment derived from cowhide. The composition may be administered to the eye of a human subject for reducing the expression of vascular endothelial growth factor A (VEGFA) gene, interleukin-1 beta (IL-1?) gene, and/or interleukin-8 (IL-8) gene.

Abstract: The present invention provides a novel multi-functional peptide that effectively regulates the activity of immune cells while also exhibiting excellent antibacterial activity against various bacteria such as Gram-negative bacteria and Gram-positive bacteria.

Abstract: The present invention is directed to a method of identifying autism spectrum disorder (ASD) phenotype 1 patients, wherein the method comprises: administering an Nrf2-activator to an ASD patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD, and identifying the ASD patient as an ASD phenotype 1 patient if the patient shows a negative response after administration of the Nrf2-activator. Likewise, the present invention is directed to a method for classifying autism spectrum disorder (ASD) phenotype 1 patients, the method comprising: administering an Nrf2-activator to a subject, and observing if the subject shows a negative response after administration of the Nrf2-activator, in which the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD and in which the negative response supports classification of the subject as an ASD phenotype 1 patient.

Abstract: The present invention is directed to a method for differentiating between ASD phenotype 1, phenotype 2 and other ASD patients, wherein the method comprises: administering an Nrf2-activator to a subject, and identifying the subject as an ASD phenotype 1 patient if the subject shows a negative response, as a phenotype 2 patient if he shows a positive response and as another ASD patient if he does not show a positive nor a negative response, wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD.

Abstract: Eleven synthetic neurokinin A peptide analogs are provided as therapeutic compounds for inducing voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). This control over when and where individuals void offers a drastic improvement in quality of life.

Abstract: The present disclosure relates to a novel recombinant BAF57 fusion protein and the use thereof as a composition capable of effectively preventing or treating inflammatory disease, immune-related disease or cancer. The fusion protein provided in the present disclosure may be delivered into cells, bind to BAF155 or other BAF complex subunit, and act as a competitive inhibitor of BAF57 present in the cell, thereby lowering the expression level of BAF57 by a protein degradation mechanism, thereby effectively preventing, ameliorating or treating various diseases such as inflammatory disease, immune-related disease or cancer.

Abstract: Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed.

Abstract: This disclosure provides peptide conjugates that are useful for inhibiting the progression of a hyperproliferative disorder, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, enhancing a response to a vaccine, or inhibiting the progression of a synucleinopathy.

Abstract: In some aspects, the present invention provides certain combination therapies comprising compstatin analogs.

Abstract: The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy.

Abstract: Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism.

Abstract: Disclosed are compositions and methods for the reduction of C5a mediated immune inflammation. The methods, in various aspects, may include the step of administering a C5aR antagonist to a subject in need of such treatment. In one aspect, the subject in need may have a lysosomal acid storage disease. Therapeutic kits and articles of manufacture are also disclosed.

Abstract: Methods of treating a cancer in a patient are provided. The methods can include obtaining a tumor sample from a patient, detecting whether CCNG1 gene expression is present in the tumor sample, diagnosing the patient with a CCNG1 inhibitor-responsive cancer when the presence of CCNG1 gene expression in the tumor sample is detected, and/or administering an effective amount of a CCNG1 inhibitor to the diagnosed patient. CCNG1 inhibitors can include a viral vector having a binding peptide that is configured to bind one or more signature (SIG) elements of an invading tumor and at least one cytocidal gene. CCNG1 inhibitors including cell penetrating peptides are also provided.

Abstract: The present disclosure provides cell-penetrating nucleic acid nanostructures well suited as transfection reagents for the delivery of bioactive agents to cells both in vivo and in vitro for research, diagnostic, and/or therapeutic purposes.

Abstract: The present invention relates to methods for identifying, assessing, preventing, and treating metabolic disorders and modulating metabolic processes using Slit2.